Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study

The study investigated the treatment and prognosis of advanced-stage extranodal natural killer/T-cell lymphoma (ENKTL). With a median follow-up of 75.03 months, the median overall survival (mOS) for the 195 newly diagnosed stage III/IV ENKTL patients was 19.43 months, and estimated 1-, 2-, 3- and 5-...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2023-11, Vol.153 (9), p.1643-1657
Main Authors: Wei, Yu-Ce, Qi, Fei, Zheng, Bao-Min, Zhang, Chang-Gong, Xie, Yan, Chen, Bo, Liu, Wei-Xin, Liu, Wei-Ping, Fang, Hui, Qi, Shu-Nan, Zhang, Di, Chai, Yue, Li, Ye-Xiong, Wang, Wei-Hu, Song, Yu-Qin, Zhu, Jun, Dong, Mei
Format: Article
Language:English
Subjects:
Anthracycline
Asparaginase
Cancer
Chemotherapy
Gemcitabine
Hematopoietic stem cells
Intensive care
Lymphoma
Medical prognosis
Medical research
Multivariate analysis
Natural killer cells
Patients
Radiation therapy
Remission
Stem cell transplantation
Survival analysis
T-cell lymphoma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study investigated the treatment and prognosis of advanced-stage extranodal natural killer/T-cell lymphoma (ENKTL). With a median follow-up of 75.03 months, the median overall survival (mOS) for the 195 newly diagnosed stage III/IV ENKTL patients was 19.43 months, and estimated 1-, 2-, 3- and 5-year OS were 59.5%, 46.3%, 41.8% and 35.1%, respectively. Chemotherapy (CT) + radiotherapy (RT) compared to CT alone (P = .007), and hematopoietic stem cell transplantation (HSCT) compared to non-HSCT (P  0.05). First-line "intensive therapy," including CT (particularly Gem + Aspa regimens), RT, HSCT and alternative chidamide MT, was proposed and could improve long-term survival for advanced-stage ENKTLs. Ongoing prospective clinical studies may shed further light on the value of chidamide MT.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.34672